Stanley Druckenmiller's Duquesne Family Office significantly cut its stake in Teva Pharmaceutical Industries by nearly 74% during the second quarter of 2026. According to regulatory filings, which disclose holdings with a delay, the firm's position was reduced from 2.38 million shares to 625,000. This trade decreased the portfolio weight of Teva from over 2% to just 0.41%.
The reduction follows a period where Druckenmiller had been consistently adding to the Teva position for several quarters. The sale occurred during a quarter where Teva reported mixed financial results on July 29, 2026, with a significant earnings-per-share miss but a revenue beat driven by its innovative drug portfolio. No specific commentary from Druckenmiller on the reason for the trade has been made public.